Search Results - "Coates, S A"

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 by Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thürlimann, B., Senn, H.-J.

“…The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes…”
Get full text

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 by Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, Kathy S., André, Fabrice, Bergh, Jonas, Bonnefoi, Hervé, Bretel-Morales, Denisse, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Coates, Alan S., Colleoni, Marco, Costa, Alberto, Curigliano, Giuseppe, Davidson, Nancy E., Di Leo, Angelo, Ejlertsen, Bent, Forbes, John F., Gelber, Richard D., Gnant, Michael, Goldhirsch, Aron, Goodwin, Pamela, Goss, Paul E., Harris, Jay R., Hayes, Daniel F., Hudis, Clifford A., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Loibl, Sibylle, Morrow, Monica, Namer, Moise, Kent Osborne, C., Partridge, Ann H., Penault-Llorca, Frédérique, Perou, Charles M., Piccart-Gebhart, Martine J., Pritchard, Kathleen I., Rutgers, Emiel J.T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Untch, Michael, Viale, Giuseppe, Watanabe, Toru, Wilcken, Nicholas, Winer, Eric P., Wood, William C.

“…The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and…”
Get full text

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 by Goldhirsch, A., Ingle, J.N., Gelber, R.D., Coates, A.S., Thürlimann, B., Senn, H.-J.

“…The 11th St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting…”
Get full text

Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 by Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., Senn, H.-J.

“…The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic…”
Get full text

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) by Pestalozzi, B.C., Zahrieh, D., Price, K.N., Holmberg, S.B., Lindtner, J., Collins, J., Crivellari, D., Fey, M.F., Murray, E., Pagani, O., Simoncini, E., Castiglione-Gertsch, M., Gelber, R.D., Coates, A.S., Goldhirsch, A.

“…We sought to determine whether a high-risk group could be defined among patients with operable breast cancer in whom a search of occult central nervous system…”
Get full text

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 by Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., Senn, H. -J.

“…The 10th St Gallen (Switzerland) expert consensus meeting in March 2007 refined and extended a target-oriented approach to adjuvant systemic therapy of early…”
Get full text

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials by Huober, J., Gelber, S., Goldhirsch, A., Coates, A.S., Viale, G., Öhlschlegel, C., Price, K.N., Gelber, R.D., Regan, M.M., Thürlimann, B.

“…To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. Among 12 409 patients, 127 were recorded as invasive…”
Get full text

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial by Rabaglio, M., Sun, Z., Price, K.N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J.F., Paridaens, R.J., Colleoni, M., Pienkowski, T., Nogaret, J.-M., Láng, I., Smith, I., Gelber, R.D., Goldhirsch, A., Coates, A.S.

“…To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive…”
Get full text

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial by Viale, G., Regan, M.M., Dell'Orto, P., Mastropasqua, M.G., Maiorano, E., Rasmussen, B.B., MacGrogan, G., Forbes, J.F., Paridaens, R.J., Colleoni, M., Láng, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R.D., Price, K.N., Goldhirsch, A., Gusterson, B.A., Coates, A.S.

“…On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early…”
Get full text

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials by Clarke, M, Coates, A S, Darby, S C, Davies, C, Gelber, R D, Godwin, J, Goldhirsch, A, Gray, R, Peto, R, Pritchard, K I, Wood, W C

“…Summary Background The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which…”
Get full text

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial by Mauriac, L, Keshaviah, A, Debled, M, Mouridsen, H, Forbes, JF, Thürlimann, B, Paridaens, R, Monnier, A, Láng, I, Wardley, A, Nogaret, J-M, Gelber, RD, Castiglione-Gertsch, M, Price, KN, Coates, AS, Smith, I, Viale, G, Rabaglio, M, Zabaznyi, N, Goldhirsch, A

“…Background: Aromatase inhibitors are considered standard adjuvant endocrine treatment of postmenopausal women with hormone receptor-positive breast cancer, but…”
Get full text

Risk Factors for Locoregional Recurrence Among Breast Cancer Patients: Results From International Breast Cancer Study Group Trials I Through VII by WALLGREN, A, BONETTI, M, FORBES, J. F, PRICE, K, COATES, A. S, COLLINS, J, GELBER, R. D, GOLDHIRSCH, A, CASTIGLIONE-GERTSCH, M, HOLMBERG, S. B, LINDTNER, J, THÜRLIMANN, B, FEY, M, WERNER, I. D

“…To explore prognostic factors for locoregional failures (LRF) among women treated for invasive breast cancer within clinical trials of adjuvant therapies. The…”
Get full text

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX by Aebi, S., Sun, Z., Braun, D., Price, K.N., Castiglione-Gertsch, M., Rabaglio, M., Gelber, R.D., Crivellari, D., Lindtner, J., Snyder, R., Karlsson, P., Simoncini, E., Gusterson, B.A., Viale, G., Regan, M.M., Coates, A.S., Goldhirsch, A.

“…The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)-positive lymph node-negative breast cancer is being reassessed…”
Get full text

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience by Berclaz, G., Li, S., Price, K. N., Coates, A. S., Castiglione-Gertsch, M., Rudenstam, C.-M., Holmberg, S. B., Lindtner, J., Erien, D., Collins, J., Snyder, R., Thürlimann, B., Fey, M. F., Mendiola, C., Dudley Werner, I., Simoncini, E., Crivellari, D., Gelber, R. D., Goldhirsch, A.

“…Background: Current information on the prognostic importance of body mass index (BMI) for patients with early breast cancer is based on a variety of equivocal…”
Get full text

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer by Karlsson, P., Sun, Z., Braun, D., Price, K.N., Castiglione-Gertsch, M., Rabaglio, M., Gelber, R.D., Crivellari, D., Collins, J., Murray, E., Zaman, K., Colleoni, M., Gusterson, B.A., Viale, G., Regan, M.M., Coates, A.S., Goldhirsch, A.

“…The International Breast Cancer Study Group Trial VIII compared long-term efficacy of endocrine therapy (goserelin), chemotherapy [cyclophosphamide,…”
Get full text

First—select the target: better choice of adjuvant treatments for breast cancer patients by Goldhirsch, A, Coates, AS, Gelber, RD, Glick, JH, Thürlimann, B, Senn, H-J

“…St Gallen Expert Consensus meetings update evidence on treatment of early breast cancer every 2 years and interpret its significance for treatment of…”
Get full text

Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? by Duric, V. M., Stockler, M. R., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A. S., Simes, R. J.

“…Background: Studies of women who had adjuvant chemotherapy for early breast cancer 10–20 years ago showed that many judged small benefits sufficient to make it…”
Get full text

Symptoms of endocrine treatment and outcome in the BIG 1-98 study by Huober, J., Cole, B. F., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B.

“…There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients…”
Get full text

CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials by Keshaviah, A, Dellapasqua, S, Rotmensz, N, Lindtner, J, Crivellari, D, Collins, J, Colleoni, M, Thürlimann, B, Mendiola, C, Aebi, S, Price, KN, Pagani, O, Simoncini, E, Castiglione Gertsch, M, Gelber, RD, Coates, AS, Goldhirsch, A

“…Background: We evaluated the ability of CA15-3 and alkaline phosphatase (ALP) to predict breast cancer recurrence. Patients and methods: Data from seven…”
Get full text

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial by Coombes, RC, Prof, Kilburn, LS, MSc, Snowdon, CF, MSc, Paridaens, R, Prof, Coleman, RE, Prof, Jones, SE, MD, Jassem, J, Prof, Van de Velde, CJH, Prof, Delozier, T, MD, Alvarez, I, MD, Del Mastro, L, MD, Ortmann, O, Prof, Diedrich, K, Prof, Coates, AS, Prof, Bajetta, E, Prof, Holmberg, SB, MD, Dodwell, D, MD, Mickiewicz, E, MD, Andersen, J, DMSc, Lønning, PE, Prof, Cocconi, G, Prof, Forbes, J, Prof, Castiglione, M, Prof, Stuart, N, MD, Stewart, A, MD, Fallowfield, LJ, Prof, Bertelli, G, MD, Hall, E, PhD, Bogle, RG, MD, Carpentieri, M, PhD, Colajori, E, MD, Subar, M, MD, Ireland, E, MSc, Bliss, JM, Prof

“…Summary Background Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after…”
Get full text